These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38361351)

  • 1. Sotatercept for Pulmonary Arterial Hypertension in the Inpatient Setting.
    Torbic H; Tonelli AR
    J Cardiovasc Pharmacol Ther; 2024; 29():10742484231225310. PubMed ID: 38361351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Pulmonary Arterial Hypertension in the ICU.
    Torbic H
    J Pharm Pract; 2019 Jun; 32(3):303-313. PubMed ID: 30909801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)?
    Doggrell SA
    Expert Opin Biol Ther; 2023; 23(7):589-593. PubMed ID: 37269300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
    Hoeper MM; Badesch DB; Ghofrani HA; Gibbs JSR; Gomberg-Maitland M; McLaughlin VV; Preston IR; Souza R; Waxman AB; Grünig E; Kopeć G; Meyer G; Olsson KM; Rosenkranz S; Xu Y; Miller B; Fowler M; Butler J; Koglin J; de Oliveira Pena J; Humbert M;
    N Engl J Med; 2023 Apr; 388(16):1478-1490. PubMed ID: 36877098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPECTRA Phase 2b Study: Impact of Sotatercept on Exercise Tolerance and Right Ventricular Function in Pulmonary Arterial Hypertension.
    Waxman AB; Systrom DM; Manimaran S; de Oliveira Pena J; Lu J; Rischard FP
    Circ Heart Fail; 2024 May; 17(5):e011227. PubMed ID: 38572639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
    Humbert M; McLaughlin V; Gibbs JSR; Gomberg-Maitland M; Hoeper MM; Preston IR; Souza R; Waxman A; Escribano Subias P; Feldman J; Meyer G; Montani D; Olsson KM; Manimaran S; Barnes J; Linde PG; de Oliveira Pena J; Badesch DB;
    N Engl J Med; 2021 Apr; 384(13):1204-1215. PubMed ID: 33789009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Health Model Predicting the Long-Term Impact of Sotatercept on Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension (PAH).
    McLaughlin V; Alsumali A; Liu R; Klok R; Martinez EC; Nourhussein I; Bernotas D; Chevure J; Pausch C; De Oliveira Pena J; Lautsch D; Hoeper MM
    Adv Ther; 2024 Jan; 41(1):130-151. PubMed ID: 37851297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical Management of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension.
    Caputo A; Papa S; Manzi G; Laviola D; Recchioni T; Severino P; Lavalle C; Maestrini V; Mancone M; Badagliacca R; Vizza CD
    Curr Heart Fail Rep; 2023 Aug; 20(4):263-270. PubMed ID: 37486563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADAMTS8 Promotes the Development of Pulmonary Arterial Hypertension and Right Ventricular Failure: A Possible Novel Therapeutic Target.
    Omura J; Satoh K; Kikuchi N; Satoh T; Kurosawa R; Nogi M; Ohtsuki T; Al-Mamun ME; Siddique MAH; Yaoita N; Sunamura S; Miyata S; Hoshikawa Y; Okada Y; Shimokawa H
    Circ Res; 2019 Oct; 125(10):884-906. PubMed ID: 31556812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension.
    Omura J; Habbout K; Shimauchi T; Wu WH; Breuils-Bonnet S; Tremblay E; Martineau S; Nadeau V; Gagnon K; Mazoyer F; Perron J; Potus F; Lin JH; Zafar H; Kiely DG; Lawrie A; Archer SL; Paulin R; Provencher S; Boucherat O; Bonnet S
    Circulation; 2020 Oct; 142(15):1464-1484. PubMed ID: 32698630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Immunogenicity on the Pharmacokinetics, Efficacy, and Safety of Sotatercept in a Phase III Study of Pulmonary Arterial Hypertension.
    Liao K; Mackenzie H; Ait-Oudhia S; Manimaran S; Zeng Y; Akers T; Yun T; de Oliveira Pena J
    Clin Pharmacol Ther; 2024 Mar; 115(3):478-487. PubMed ID: 38012534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrastructural Changes of the Right Ventricular Myocytes in Pulmonary Arterial Hypertension.
    Shults NV; Kanovka SS; Ten Eyck JE; Rybka V; Suzuki YJ
    J Am Heart Assoc; 2019 Mar; 8(5):e011227. PubMed ID: 30807241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension.
    Joshi SR; Liu J; Bloom T; Karaca Atabay E; Kuo TH; Lee M; Belcheva E; Spaits M; Grenha R; Maguire MC; Frost JL; Wang K; Briscoe SD; Alexander MJ; Herrin BR; Castonguay R; Pearsall RS; Andre P; Yu PB; Kumar R; Li G
    Sci Rep; 2022 May; 12(1):7803. PubMed ID: 35551212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Navigating the Sotatercept landscape: A meta-analysis of clinical outcomes.
    Nasrollahizadeh A; Soleimani H; Nasrollahizadeh A; Hashemi SM; Hosseini K
    Clin Cardiol; 2024 Jan; 47(1):e24173. PubMed ID: 37819149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension.
    Bisserier M; Katz MG; Bueno-Beti C; Brojakowska A; Zhang S; Gubara S; Kohlbrenner E; Fazal S; Fargnoli A; Dorfmuller P; Humbert M; Hata A; Goukassian DA; Sassi Y; Hadri L
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.
    Ruopp NF; Cockrill BA
    JAMA; 2022 Apr; 327(14):1379-1391. PubMed ID: 35412560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update.
    Coons JC; Pogue K; Kolodziej AR; Hirsch GA; George MP
    Curr Cardiol Rep; 2019 Nov; 21(11):141. PubMed ID: 31758342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial.
    Souza R; Badesch DB; Ghofrani HA; Gibbs JSR; Gomberg-Maitland M; McLaughlin VV; Preston IR; Waxman AB; Grünig E; Kopeć G; Meyer G; Olsson KM; Rosenkranz S; Lin J; Johnson-Levonas AO; de Oliveira Pena J; Humbert M; Hoeper MM
    Eur Respir J; 2023 Sep; 62(3):. PubMed ID: 37696565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving transitions of care for critically ill adult patients on pulmonary arterial hypertension medications.
    Martirosov AL; Smith ZR; Hencken L; MacDonald NC; Griebe K; Fantuz P; Grafton G; Hegab S; Ismail R; Jackson B; Kelly B; Miller M; Awdish R
    Am J Health Syst Pharm; 2020 Jun; 77(12):958-965. PubMed ID: 32495842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-Beat Right Ventricular-Arterial Coupling Predicts Clinical Worsening in Pulmonary Arterial Hypertension.
    Hsu S; Simpson CE; Houston BA; Wand A; Sato T; Kolb TM; Mathai SC; Kass DA; Hassoun PM; Damico RL; Tedford RJ
    J Am Heart Assoc; 2020 May; 9(10):e016031. PubMed ID: 32384024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.